[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-346243-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-346243-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","elevated-levels-of-slc38a1-are-correlated-with-an-unfavorable-prognosis-as-well-as-accelerated-cell-proliferation-and-metastasis-in-lung-adenocarcinoma","Elevated Levels of SLC38A1 Are Correlated with an Unfavorable Prognosis - as Well as Accelerated Cell Proliferation and Metastasis in Lung Adenocarcinoma","","SLC38A1 is reported as a carcinogenic factor in several cancers, yet its function in lung adenocarcinoma (LUAD) is insufficiently described. This study evaluates SLC38A1 expression using TCGA, XENA, and LCE data, and validates findings in 10 LUAD patient samples. Prognostic nomograms and risk models are built, and cellular mechanisms are tested with CCK-8, migration and invasion assays, Western blotting, and GO/KEGG analyses. Results show that SLC38A1 is overexpressed and linked to poor survival plus immune-related infiltration and aggressive progression.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/elevated-levels-of-slc38a1-are-correlated-with-an-unfavorable-prognosis-as-well-as-accelerated-cell-proliferation-and-metastasis-in-lung-adenocarcinoma/346243/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/elevated-levels-of-slc38a1-are-correlated-with-an-unfavorable-prognosis-as-well-as-accelerated-cell-proliferation-and-metastasis-in-lung-adenocarcinoma/346243.png","ImageObject",300,407,{"name":42,"@type":43},"Jiven","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-02","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is SLC38A1 and why is it important in this study?","Question",{"text":63,"@type":64},"SLC38A1 is described as a glutamine transporter implicated in cancer pathogenesis. The study focuses on its previously underexplored role in lung adenocarcinoma (LUAD).","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was SLC38A1 expression and its clinical relevance assessed in LUAD?",{"text":68,"@type":64},"The researchers used expression data from TCGA, XENA, and LCE databases, then validated results in samples from 10 LUAD patients. They also constructed prognostic nomograms and risk models based on SLC38A1.",{"name":70,"@type":61,"acceptedAnswer":71},"What relationship did the study find between SLC38A1 and LUAD patient outcomes?",{"text":72,"@type":64},"Higher SLC38A1 expression correlated with worse overall survival, disease-free survival, and progression-free interval, and was identified as an independent risk factor in LUAD.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},346243,1790798405,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":109,"preview_page_count":33,"preview_urls":146},1099513958607,"https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399","Xia et al. BMC Cancer (2026) 26:20 BMC Cancer  \n[https://doi.org/10.1186/s12885-025-15329-9](https://doi.org/10.1186/s12885-025-15329-9)  \nRESEARCH Open Access  \nElevated levels of SLC38A1 are correlated with an unfavorable prognosis, as well as accelerated cell proliferation and metastasis in lung adenocarcinoma  \nTian Xia 1, Qun-Xian Zhang2, Chang Liu 1, Ming-Liang Wang 1, Peng Miao 1, Dan Li3* and Li Wei 1*  \nAbstract  \nBackground SLC38A1 has been identified as a carcinogenic factor in the progression of colorectal, gastric, pancreatic, and other cancers. However, its involvement in lung adenocarcinoma (LUAD) remains unexplored in the literature.  \nMethods The expression levels, diagnostic relevance, and clinical significance of SLC38A1 in LUAD were evaluated using data from theTCGA, XENA, and LCE databases, along with validation in samples from 10 LUAD patients at our hospital. Prognostic nomograms and risk models based on SLC38A1 were constructed. The functional roles and mechanisms of SLC38A1 in LUAD were investigated through CCK-8 assays, migration and invasion assays, Western blotting, GO and KEGG pathway analyses, and correlation analysis to explore its relationship with the immune microenvironment.  \nResults SLC38A1 was overexpressed in both unpaired and paired LUAD samples, with a marked increase in earlystage LUAD. Overexpression of SLC38A1 correlated with diagnostic accuracy and poor overall survival (HR = 1 . 53; 95% CI = 1 .15–2. 04), disease-free survival (HR = 1 . 59; 95% CI = 1 .1–2. 3), and progression-free interval (HR = 1 . 51; 95% CI = 1 .16–1. 97) . COX regression analysis identified SLC38A1 overexpression as an independent risk factor for poor prognosis in LUAD patients. High-risk scores and nomograms associated with SLC38A1 were significantly linked to adverse clinical outcomes. Genes co-expressed with SLC38A1 were involved in nuclear division, DNA replication, and the cell cycle. Silencing of SLC38A1 expression inhibited LUAD cell growth and migration. Furthermore, SLC38A1 overexpression was associated with immune cell infiltration in LUAD, including Th2 cells, Tcm, T helper cells, and immune markers such as CD8A, CD8B, and CTLA4 .  \nConclusion SLC38A1 is upregulated in LUAD, and its overexpression is associated with poor prognosis, diagnostic accuracy, and immune cell infiltration. SLC38A1-based risk models and nomograms offer potential predictive tools for assessing prognosis in LUAD patients.  \n*Correspondence: Dan Li[lq949661259@163.com](lq949661259@163.com)[ ](lq949661259@163.com)Li Wei  \n[wlixxt@sina.com](wlixxt@sina.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/l](vecommons.org/l)icenses/by-nc-nd/4.0/.  \nXia et al. BMC Cancer (2026) 26:20 Page 2 of 16  \nKeywords SLC38A1, LUAD, Immune cell infiltration, Prognosis, Meta-analysis  \nBackground  \nThe Solute Carrier (SLC) family regulates the transport and absorption of amino acids, nucleotides, su","cbCainWoF28jq3yq","https://ap.wps.com/l/cbCainWoF28jq3yq","pdf",7410078,16,"English","# Background\n# Materials and methods\n## Source of LUAD patients\n# Results\n# Conclusion","[{\"question\":\"What is SLC38A1 and why is it important in this study?\",\"answer\":\"SLC38A1 is described as a glutamine transporter implicated in cancer pathogenesis. The study focuses on its previously underexplored role in lung adenocarcinoma (LUAD).\"},{\"question\":\"How was SLC38A1 expression and its clinical relevance assessed in LUAD?\",\"answer\":\"The researchers used expression data from TCGA, XENA, and LCE databases, then validated results in samples from 10 LUAD patients. They also constructed prognostic nomograms and risk models based on SLC38A1.\"},{\"question\":\"What relationship did the study find between SLC38A1 and LUAD patient outcomes?\",\"answer\":\"Higher SLC38A1 expression correlated with worse overall survival, disease-free survival, and progression-free interval, and was identified as an independent risk factor in LUAD.\"}]","Elevated Levels of SLC38A1 Are Correlated with an Unfavorable Prognosis - as Well as Accelerated Cell Proliferation and Metastasis in Lung Adenocarcinoma | PDF",1790060605,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dbf88acca5c9e3c428808af4a711e35d.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7911c41f5ccb3e2ae5182291cd5abc91.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4725a766c042ff95dd97c5163406763c.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7344731d47af5c2ff6f963c3ef551c1d.webp",980,1306]